АкушерствоАнатомияАнестезиологияВакцинопрофилактикаВалеологияВетеринарияГигиенаЗаболеванияИммунологияКардиологияНеврологияНефрологияОнкологияОториноларингологияОфтальмологияПаразитологияПедиатрияПервая помощьПсихиатрияПульмонологияРеанимацияРевматологияСтоматологияТерапияТоксикологияТравматологияУрологияФармакологияФармацевтикаФизиотерапияФтизиатрияХирургияЭндокринологияЭпидемиология

Вергейчик Г. И.,

координатор конференции,

к.м.н., доцент,

доцент кафедры онкологии, с курсом лучевой

диагностики и лучевой терапии, заведующая

отделом научно-медицинской информации

УО «Гомельский государственный

медицинский университет»

Cancer of the cervix uteri has been historically the number one cancer in women. In spite of the opportunities offered by screening programs still is the second most common cancer among women worldwide, with an estimated 493,000 new cases and 274,000 deaths in 2002. Cervical cancer clusters in developing countries, where 80 % of the cases occur and account for at least 15 % of all female cancers. In some of these populations the cumulative risk of developing cervical cancer is estimated in the range of 1.5 to 3%, while in developed countries it accounts for 3.6% of all new cancers in women with a cumulative risk of 0.8 % up to 65 years of age.

Current research is actively investigating the role of HPV infections, notably of HPV 16, in cancers of the oro-pharynx (averaged estimates of 35%) and of the oral cavity (averaged estimates of 20 %).

In summary HPV is now considered the second most important human carcinogen accounting for 5 % of human cancer 10 % of cancer in women and 15 % of cancer in women in developing countries. The fraction linked to HPV 16 and 18 that are potentially preventable with current HPV vaccines account for close to 550,000 new cases per year worldwide.

Professor F. Xavier Bosch

Дата добавления: 2014-12-11 | Просмотры: 511 | Нарушение авторских прав